Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3Expanded_access 3

Sponsor

Cancer Type

CNS 3Endocrine 1

Conditions

Neuroblastoma 27Neuroendocrine Tumors 9Pheochromocytoma 8Paraganglioma 4Neoplasms 4Recurrence 3Ganglioneuroblastoma 3Neoplasm Metastasis 2Neuroectodermal Tumors 1Gastro-enteropancreatic neuroendocrine tumor 1Disease 1

Interventions

Cyclophosphamide 151Dexamethasone 140Rituximab 83fludarabine 78Cytarabine 69Lenalidomide 68Bortezomib 63fludarabine phosphate 62Gemcitabine 62venetoclax 54Etoposide 53pembrolizumab 52pomalidomide 48Paclitaxel 48Cisplatin 47Carboplatin 47Peripheral Blood Stem Cell Transplantation 46Filgrastim 40Radiotherapy 39Calcium Dobesilate 36Busulfan 36Methotrexate 34Melphalan 34Bevacizumab 33carfilzomib 32Cyclosporine 32Azacitidine 32Mycophenolic Acid 29Vincristine 28Temozolomide 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Recurrence × 3-Iodobenzylguanidine × Clear all
NCT01313936 2019-04-29

High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma

University of California, San Francisco

Phase 1 Completed
32 enrolled 8 charts
CNS

Neoplasms, Neuroblastoma, Recurrence

NCT01413503 2018-09-18

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

University of California, San Francisco

Phase 2 Completed
50 enrolled 7 charts
CNSEndocrine

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence

NCT00013806 2005-06-24

CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study

National Center for Research Resources (NCRR)

Phase 2 Unknown
CNS

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡